Despite a superior revenue outlook, the company isn't trading at a higher P/S due to potential risks like not meeting analysts' revenue projections in tough industry conditions. Investors anticipate future revenue volatility.
Bio-Rad's unstable profits and stale growth over the past three years are worrying. Despite a rise in stocks, long-term performance lacks strength. If fundamentals signal sustainable growth, the current sell-off could be a chance.
Bio-Rad實驗室股票討論區
近4年來持續有高額出售證券收益,2022年爲52億出售證券虧損,因此造成了淨利潤大幅超過營業利潤的情況。5年平均淨利爲13億。
目前市值112.5億,如果按平均淨利計算市盈率爲8.6。
5年中營業利潤最高爲5億,對應市盈率爲22.5。
估值是高還是低取決於未來出售證券收益的規模和盈虧情況,無法判斷。
暫無評論